Smart Scholars🛡 Scholar Shield🏛 Research Integrity Desk🧩 Portfolio Console📰 Journals🔧 DOI MembersTools🔎 Journal AuditGI GetIndexedDr DOI Doctor

Cite this DOI

10.46243/jst.2021.v6.i03.pp240-246 · Effect of Aescin on Inflammatory Responses in a Diabetic Peripheral Neuropathy Rat Model by Modulating HMGB1 and RAGE Levels

APA (7th edition)

T.Swathi, T.Vijayalakshmi, & Zuberiya, M. (2021). Effect of Aescin on Inflammatory Responses in a Diabetic Peripheral Neuropathy Rat Model by Modulating HMGB1 and RAGE Levels. *Journal of Science & Technology*, *06*(03), 240–246. https://doi.org/10.46243/jst.2021.v6.i03.pp240-246

⬇ text Italics are shown as *asterisks* in plain text — the journal or book title and the volume.

BibTeX

@article{tswathi2021effect,
  author    = {T.Swathi and T.Vijayalakshmi and Zuberiya, Maheen},
  title     = {{Effect of Aescin on Inflammatory Responses in a Diabetic Peripheral Neuropathy Rat Model by Modulating HMGB1 and RAGE Levels}},
  journal   = {Journal of Science \& Technology},
  year      = {2021},
  month     = {jun},
  volume    = {06},
  number    = {03},
  pages     = {240--246},
  publisher = {Longman Publishers},
  issn      = {2456-5660},
  doi       = {10.46243/jst.2021.v6.i03.pp240-246},
  url       = {https://doi.org/10.46243/jst.2021.v6.i03.pp240-246},
  language  = {en},
  abstract  = {The diabetic peripheral neuropathy pain model was constructed after 95 Sprague Dawley rats had been randomly divided among blank reference and model groups. Aescin low-dose group (0.5 mg/kg), aescin medium-dose group (1.0 mg/kg), aescin high-dose group (1.5 mg/kg), and positive control group (0.25 mg/ kg mecobalamin) were then randomly assigned to the simulation group following successful modeling. At the conclusion of the study, the mean sciatic nerve conduction velocity was determined, blood glucose in addition to the amount of inflammatory factors tumor necrosis factor-alpha, interleukin-6, and interleukin-1 were determined, and sciatic nerve cells from mice in all groups were collected for Western blot to identify the protein levels of high mobility group box 1 and receptor for advanced glycation end products. The mean sciatic nerve conduction velocity of the medium and high-dose groups of aescin was higher than those of the model control (p<0.05); rat blood glucose content, the contents of inflammatory factors interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha as well as the protein expression of high mobility group box 1 and receptor for advanced glycation end products in sciatic nerve tissue were lower and the body mass was higher than that of the model control group (p<0.05). Comparing the high-dose aescin group as well as the positive control group, there had been no discernible change in the aforementioned indices (p>0.05). Aescin is able to effectively improve the inflammatory response in the body by regulating high mobility group box 1-receptor for advanced glycation end products levels and slow down diabetic peripheral neuropathy caused by the inflammatory response.}
}

⬇ .bib

RIS (EndNote, Zotero, Mendeley)

TY  - JOUR
TI  - Effect of Aescin on Inflammatory Responses in a Diabetic Peripheral Neuropathy Rat Model by Modulating HMGB1 and RAGE Levels
AU  - T.Swathi
AU  - T.Vijayalakshmi
AU  - Zuberiya, Maheen
JO  - Journal of Science & Technology
PY  - 2021
DA  - 2021/06/27/
VL  - 06
IS  - 03
SP  - 240
EP  - 246
PB  - Longman Publishers
SN  - 2456-5660
LA  - en
AB  - The diabetic peripheral neuropathy pain model was constructed after 95 Sprague Dawley rats had been randomly divided among blank reference and model groups. Aescin low-dose group (0.5 mg/kg), aescin medium-dose group (1.0 mg/kg), aescin high-dose group (1.5 mg/kg), and positive control group (0.25 mg/ kg mecobalamin) were then randomly assigned to the simulation group following successful modeling. At the conclusion of the study, the mean sciatic nerve conduction velocity was determined, blood glucose in addition to the amount of inflammatory factors tumor necrosis factor-alpha, interleukin-6, and interleukin-1 were determined, and sciatic nerve cells from mice in all groups were collected for Western blot to identify the protein levels of high mobility group box 1 and receptor for advanced glycation end products. The mean sciatic nerve conduction velocity of the medium and high-dose groups of aescin was higher than those of the model control (p<0.05); rat blood glucose content, the contents of inflammatory factors interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha as well as the protein expression of high mobility group box 1 and receptor for advanced glycation end products in sciatic nerve tissue were lower and the body mass was higher than that of the model control group (p<0.05). Comparing the high-dose aescin group as well as the positive control group, there had been no discernible change in the aforementioned indices (p>0.05). Aescin is able to effectively improve the inflammatory response in the body by regulating high mobility group box 1-receptor for advanced glycation end products levels and slow down diabetic peripheral neuropathy caused by the inflammatory response.
DO  - 10.46243/jst.2021.v6.i03.pp240-246
UR  - https://doi.org/10.46243/jst.2021.v6.i03.pp240-246
ER  -

⬇ .ris

CSL-JSON

{
    "type": "article-journal",
    "id": "10.46243/jst.2021.v6.i03.pp240-246",
    "DOI": "10.46243/jst.2021.v6.i03.pp240-246",
    "URL": "https://doi.org/10.46243/jst.2021.v6.i03.pp240-246",
    "title": "Effect of Aescin on Inflammatory Responses in a Diabetic Peripheral Neuropathy Rat Model by Modulating HMGB1 and RAGE Levels",
    "source": "Smart Scholars DOI Registry",
    "container-title": "Journal of Science & Technology",
    "author": [
        {
            "family": "T.Swathi"
        },
        {
            "family": "T.Vijayalakshmi"
        },
        {
            "family": "Zuberiya",
            "given": "Maheen"
        }
    ],
    "issued": {
        "date-parts": [
            [
                2021,
                6,
                27
            ]
        ]
    },
    "volume": "06",
    "issue": "03",
    "page": "240-246",
    "publisher": "Longman Publishers",
    "language": "en",
    "abstract": "The diabetic peripheral neuropathy pain model was constructed after 95 Sprague Dawley rats had been randomly divided among blank reference and model groups. Aescin low-dose group (0.5 mg/kg), aescin medium-dose group (1.0 mg/kg), aescin high-dose group (1.5 mg/kg), and positive control group (0.25 mg/ kg mecobalamin) were then randomly assigned to the simulation group following successful modeling. At the conclusion of the study, the mean sciatic nerve conduction velocity was determined, blood glucose in addition to the amount of inflammatory factors tumor necrosis factor-alpha, interleukin-6, and interleukin-1 were determined, and sciatic nerve cells from mice in all groups were collected for Western blot to identify the protein levels of high mobility group box 1 and receptor for advanced glycation end products. The mean sciatic nerve conduction velocity of the medium and high-dose groups of aescin was higher than those of the model control (p<0.05); rat blood glucose content, the contents of inflammatory factors interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha as well as the protein expression of high mobility group box 1 and receptor for advanced glycation end products in sciatic nerve tissue were lower and the body mass was higher than that of the model control group (p<0.05). Comparing the high-dose aescin group as well as the positive control group, there had been no discernible change in the aforementioned indices (p>0.05). Aescin is able to effectively improve the inflammatory response in the body by regulating high mobility group box 1-receptor for advanced glycation end products levels and slow down diabetic peripheral neuropathy caused by the inflammatory response.",
    "ISSN": "2456-5660"
}

⬇ .json What citeproc and reference managers read; the DOI system hands it out for Accept: application/vnd.citationstyles.csl+json, and so does this registry's resolver.

From the record as registered (version 2) — the record and its history. Programs: https://registry.smartscholars.in/api.php?action=cite&doi=10.46243%2Fjst.2021.v6.i03.pp240-246 gives all four in one JSON answer.

Everything Smart Scholars runsNine sites, one account. A journal starts at the audit; an author starts at Scholar Shield.

For journals & publishers

Start with the audit — it is free, and it is the gate to everything else.

DOI care

Nine services on one journal profile — each previews first and acts only on your approval.

For authors & researchers

Free to use. Nothing you check is shared with the journal.

For institutions, sponsors & DOI operators

Smart Scholars

Mon–Sat, 10:00–19:00 IST. The Ask AI button on every page answers about our services at any hour.

News

Policies

What we can register a DOI for

20 kinds of record, one account, one place. Every one gets a DOI that resolves, metadata that indexes read, and a record that stays correct afterwards.
Journals
  • Journal articles
  • Journal titles
  • Pending publications
  • Peer reviews
  • Preprints & posted content
Books & conferences
  • Books
  • Book chapters
  • Book series
  • Book sets
  • Conference proceedings
  • Proceedings series
  • Conference papers
Other research output
  • Theses & dissertations
  • Reports & working papers
  • Report series
  • Standards
  • Databases
  • Datasets
  • Figures, tables & supplements
Funding
  • Grants & funding awards

Elsewhere

The same company, in the places our publishers already read.
Smart Scholars · Every service on one pageData from OpenAlex (openalex.org), CC0 · Crossref · ISSN Portal · DOAJContact
WhatsApp